Majority of Stockholders Support Pasithea Directors at Special Meeting
14 Dezembro 2022 - 7:17PM
Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the
“Company”), a biotechnology company focused on the discovery,
research and development of innovative treatments for central
nervous system (CNS) disorders, today announced the final results
of the Special Meeting of Stockholders (“Special Meeting”) held on
December 9, 2022.
According to the certified voting results
provided by the Independent Inspector of Elections, a significant
majority of Pasithea stockholders rejected all of the proposals
asserted by a dissident group of stockholders. Of the votes cast at
the Special Meeting, approximately 67% rejected the proposals to
remove the Company’s directors, representing approximately 12.7
million shares or approximately 44% of the total outstanding
shares. As a result, the current members of the Company’s Board
will continue to serve and oversee Pasithea’s business strategy.
The final certified results will be filed on a Form 8-K with the
Securities and Exchange Commission.
Dr. Tiago Reis Marques, Pasithea’s Chief
Executive Officer, stated, “We thank our stockholders for their
support at the Special Meeting and look forward to continue working
diligently to develop our product pipeline in an effort to provide
groundbreaking therapies for patients and drive value creation for
all Pasithea stockholders.”
About Pasithea Therapeutics
Corp.
Pasithea Therapeutics is a biotechnology company
primarily focused on the discovery, research and development of
innovative treatments for central nervous system (CNS) disorders.
With an experienced team of experts in the fields of neuroscience
and psychopharmacology, Pasithea is developing new molecular
entities for the treatment of psychiatric and neurological
disorders, including Amyotrophic Lateral Sclerosis (ALS) and
Multiple Sclerosis, Neurofibromatosis type 1 and Noonan
syndrome.
Forward Looking Statements
This press release contains statements that
constitute “forward-looking statements.” Forward-looking statements
are subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company’s filings with the the U.S. Securities and Exchange
Commission (the “SEC”). Thus, actual results could be materially
different. The Company undertakes no obligation to update these
statements whether as a result of new information, future events or
otherwise, after the date of this release, except as required by
law. Such forward-looking statements are subject to risks
(including those set forth in the Company’s public filings with the
SEC) and uncertainties which could cause actual results to differ
from the forward-looking statements.
Pasithea Therapeutics Corp. Company
Contact
Dr. Tiago Reis MarquesChief Executive OfficerE:
tiago@pasithea.com
Pasithea Therapeutics Corp. Media Contact
Paul Caminiti/Nicholas Leasure ReevemarkT: 212-433-4600 E:
PasitheaTeam@reevemark.com
Pasithea Therapeutics (NASDAQ:KTTAW)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Pasithea Therapeutics (NASDAQ:KTTAW)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024